BioCryst rises on US FDA approval for oral formulation of rare disease drug

Shares of drugmaker BioCryst Pharmaceuticals BCRX.O rise 2% to $7.73 premarket

US FDA approves co's oral pellet formulation of once-daily drug Orladeyo for pediatric patients with hereditary angioedema

Hereditary angioedema is a genetic disorder that causes episodes of swelling in different parts of a child's body, including in the face and hands

Orladeyo is a prophylactic therapy designed to prevent attacks of hereditary angioedema

Up to last close, stock up 0.8% YTD